This report is no longer available. Click here to view our current reports or contact us to discuss a custom report.

If you have previously purchased this report then please use the download links on the right to download the files.

Bioelectronic Medicine 2017-2027: Technologies, Markets, Players

Cardiac Rhythm and Nerve Stimulator Devices, the Electric Future of Medicine

Brand new for September 2017
显示全部 说明 内容、图表列表 常见问题解答 价格 Related Content
Bioelectronic medicines are amongst us today. As a general definition, they are implantable and non-implantable medical devices that use electrical stimulation to treat a handful of chronic diseases and conditions. They are inclusive of, but not limited to: pacemakers, spinal cord stimulators(SCS), deep brain stimulators (DBS) etc. Efforts into the development of more sophisticated and miniature bioelectronic medicines are in the works. Such devices can be termed, "Next generation bioelectronic medicines", these devices aim to be superior to their predecessors and will treat virtually all chronic diseases and conditions. This report, provides a complete analysis of this market, inclusive of: trends, drivers, opportunities, restraints, and key stakeholders.
Electric medicine, the future of medicine, offering new hope
Bioelectronic medicines hold the potential to change the way in which chronic diseases/ conditions are treated. Instead of taking a molecular medication (pharmaceutical), a tiny implantable electronic device will be the medication. Such devices although not currently as sophisticated as they aim to be use electrical stimulation as their form of therapy, presently, they primarily treat cardiovascular diseases, neurological diseases and neurological conditions (chronic pain). In the future, bioelectronic medicines will be smaller, more sophisticated and will treat all known chronic diseases/ conditions known to man, such devices can be termed 'next generation' bioelectronic medicines.
 
More precisely, next generation bioelectronic medicines are expected to be the size of a grain of rice, they will be attached to a nerve within the peripheral nervous system that is implicated in a disease or disorder. They will function to change or restore faulty electrical signals in such nerve, which will restore the proper function of the 'disordered' organ. Essentially, next generation bioelectronic medicines will read and write the electrical signals within the nervous system, they then will not only be therapeutics but sensors as well.
 
Next generation bioelectronic medicines are currently in development, meaning that, no true next generation bioelectronic medicine has hit the market. Researchers, as well as some start-up companies, are heavily invested in their development. The materials, design and functionality capabilities needed to fabricate these sophisticated next generation bioelectronic medicines are being assessed.
 
IDTechEx, predicts that the bioelectronic medicine market value for bioelectronic medicines (current-day) is approximately $ 16 billion, this number will conservatively increase in the up and coming years. While this market is saturated, efforts in the continuation of bioelectronic medicines have offered a plethora of opportunities for new entrants.
 
(Fig 1) Full market value for bioelectronic medicines 2017-2020
Source: IDTechEx
Market Trends and Drivers
Key drivers and trends within this field are an ageing population, an increase in chronic disease, an unmet need that current medical standards of care (pharmaceuticals, physical therapy, etc.) have not met, an increased amount of funding for the development of next generation bioelectronic medicines (over 1 Billion), an increased number of patents being filed for electrical stimulation (neuromodulation) devices, and the incorporation of IOT (internet of things) into this device.
Report segmentation
In this report, the market is segmented by: product, disease indication, product type, end-user and region.
 
(Fig 2) Full market segmentation
Source: IDTechEx
 
The forecast in this report shows the value of current day bioelectronic medicines assessed by sourcing through relevant company's annual reports. While this report is useful to a wide range of audiences, the report may be most useful to medical device suppliers.
 
In this report, a 10-year forecast is given, the key players in present day and future bioelectronic medicines are identified and targeted. The report is inclusive of the worldwide potential of bioelectronic medicines, with the United States leading the way. Research methods were inclusive of attending pertinent conferences related to this topic, patent searches, scoping through annual reports, speaking to experts within this field as well as interviewing relevant companies within this realm.
从 IDTechEx 访问分析师
所有报告购买订单均包括与一名专家分析师进行 30 分钟的电话交谈，专家分析师将帮助您将报告中的重要发现与您正在处理的业务问题联系起来。这需要在购买报告后的三个月内使用。
更多信息
如果您对这一报告有任何疑问，请随时联系我们的报告团队 research@IDTechEx.com 或致电我们的销售经理：

AMERICAS (USA): +1 617 577 7890
ASIA (Japan and Korea): +81 3 3216 7209
EUROPE (UK) +44 1223 812300
1.EXECUTIVE SUMMARY
1.1.Bioelectronic Medicines: Defined
1.2.Why Bioelectric medicine? Side-effects
1.3.Market value of current day bioelectronic medicines: 2017-2027
1.4.Market potential: Next generation bioelectronic medicines
1.5.Pictorial representation of 'Bioelectronic medicine' devices
1.6.Trends: Bioelectronic medicine
1.7.Investment in the development of advanced bioelectric medicine
1.7.1.Sample of some of the investments that have been made for the development of next-generation bioelectronic medicines
1.8.Market segmentation : 'Bioelectronic medicine'
1.9.Key Players: By Product Type
1.10.Forecasted market maturity level
2.INTRODUCTION
2.1.Introduction: Scope of report
2.1.1.Introduction: Initiation, emergence and trends in bioelectronic medicines
2.2.Definitions : Assortment of commonly used terms throughout this report
2.3.Disease: Disordered function within the body
2.4.Neurological disorder: Pain
2.5.Chronic Disease: Prevalence of diabetes, current and years to come
2.6.Molecular structures : Pharmaceuticals as treatments for disease
2.6.1.Molecular structures : Applications and methods of delivery for pharmaceuticals
2.6.2.Molecular structures : The path of pharmaceuticals in the body
2.7.Electrical impulse medicines: Origins of electrical stimulation as a therapy in the treatment of disease and medical conditions
2.7.1.Electrical impulse medicines: The nervous system
2.7.2.Electrical impulse: Peripheral nervous system
2.8.Market segmentation : 'Bioelectronic medicine'
2.8.1.Market Segmentation: Product
2.8.2.Market Segmentation : Disease indications
2.8.3.Market Segmentation: Product type
2.8.4.Market Segmentation : End-user
2.8.5.Market Segmentation: Geographical region
2.9.Institutions and industries acting on new developments in next generation bioelectronic medicines
2.10.Collaboration : Overlap between different industries and institutions
2.11.Headlines : Prominent headlines concerning bioelectronic medicine, 2013-2017
2.12.Google Trends: "Bioelectronic medicine"
2.13.Timeline: illustration of the design and applicable disease indications of bioelectronic medicine from 1842- current date
2.14.Forecasted market maturity level
3.MARKET DYNAMICS: TRENDS AND DRIVERS
3.1.Trends: Bioelectronic medicine
3.2.Investment in the development of advanced bioelectric medicine
3.2.1.Investments: Anticipated investment from government agencies for the FY2017 Federal agencies BRAIN initiative
3.2.2.Investments: The BRAIN INITIATIVE
3.2.3.Investments: BRAIN initiative, DARPA sponsored, Electrical Prescriptions (ElectRx)
3.2.4.Investments: Glaxo Smith Kline interest in Bioelectronic medicine timeline
3.2.5.Investments: Stimulating Peripheral Activity to Relieve Conditions (SPARC)
3.2.6.Investments: Spin-off, Setpoint Medical
3.3.R&D: Bioelectronic Medicine | The Feinstein Institute for Medical Research
3.4.Patents: Increase in the number of patents being filed that pertain to bioelectronic medicines
3.4.1.Patents: Granted by country
3.5.FDA: High percentage PMA & 510K approvals for medical devices
3.6.Societal: Prevalence of Chronic disease
3.6.1.Societal : Ageing population
3.7.Device innovations: Internet of things
3.7.1.Device innovations: IOT, Capabilities
3.7.2.Device innovations: Responsive treatment
3.7.3.Device innovations: Miniaturization
3.8.Trends: Final thoughts
4.MARKET DYNAMICS: RESTRAINTS & CHALLENGES
4.1.Restraints & Challenges: Overview
4.2.Restraints & Challenges: European Union (EU) vs US regulations
4.3.Restraints & Challenges: FDA Approval ( US)
4.3.2.Restraints & Challenges: FDA Approval ( US), Clinical Trial
4.4.Restraints & Challenges: The issue of reimbursement
4.5.Restraints & Challenges: Last resort
4.6.Restraints & Challenges: Final thoughts
4.7.Market by product type
5.CARDIAC BIOELECTRONIC MEDICINES
5.1.Cardiac rhythm management devices : Overview
5.1.1.Cardiac rhythm management devices :Cardiac conduction system overview
5.1.2.Cardiac rhythm management devices : pathway, failure and causes
5.1.3.Cardiac rhythm management devices : Pacemaker
5.2.Bioelectronic medicines: The Components
5.2.1.Bioelectronic medicines: The pulse generator
5.2.2.Pulse generator: Casing & Connector block
5.2.3.Pulse generator: The battery
5.2.4.Pulse generator: Circuitry system
5.3.IPG : Programming
5.4.Bioelectronic medicine: Leads
5.5.Bioelectronic medicines: Electrodes
5.6.Leads: Cardiac rhythm management devices
5.7.Cardiac rhythm management devices : Pacemaker, types
5.7.1.Cardiac rhythm management devices : Pacemaker placement & function in heart
5.8.Cardiac rhythm management devices : ICD
5.8.1.Cardiac rhythm management devices : ICD components
5.9.Cardiac rhythm management devices:ICD, High-Voltage Shock Therapy
5.9.1.Cardiac rhythm management devices : ICD, types
5.9.2.Cardiac rhythm management devices :ICD , How it works in heart
5.10.Cardiac rhythm management devices : Indications for use
5.11.Cardiac rhythm management devices : The players
5.11.1.Medtronic: Cardiac Rhythm
5.11.2.Boston Scientific :Cardiac rhythm
5.11.3.St. Jude Medical: Cardiac rhythm
5.11.4.Sorin & Biotronik: Cardiac Rhythm
5.12.Cardiac Rhythm management devices: Breakdown by vendor
5.12.1.Cardiac Rhythm management devices: 'Big' three dominance
5.12.2.Cardiac Rhythm management devices (ICD): Sales by territory
5.12.3.Cardiac Rhythm management devices (Pacemaker): Sales by territory
5.12.4.Cardiac rhythm management devices: Comparisons
5.12.5.Cardiac rhythm management devices : Patent analysis
5.12.6.Cardiac rhythm management devices : Patent analysis
5.13.Trends: Cardiac rhythm management devices
5.14.Cardiac rhythm management: Players summary
5.15.Cardiac rhythm management devices : Take home messages
6.ELECTRICAL NEUROMODULATION TECHNOLOGIES : CNS & PNS
6.1.Neuromodulation : Overview
6.2.Timeline: FDA approvals electrical neuromodulation devices (Neurological)
6.3.Neuromodulation: Greater occipital nerve
6.4.Neuromodulation: Sacral Nerve
6.5.Neuromodulation: Vagus Nerve
6.6.Neuromodulation: Trigeminal Nerve
6.7.Neuromodulation: Afferent & Efferent sensory nerves
6.8.Neuromodulation: Spinal Cord
6.9.Neuromodulation: Dorsal root ganglia
6.10.Neuromodulation: Brain
6.11.Neuromodulation: Components & IPG Platform
6.12.Peripheral Nervous System Electro Stimulators
6.13.PNS: Surgically implanted
6.14.Components: Sacral + Vagus neuromodulators
6.14.1.Surgically Implanted PNS stimulators: Depression
6.14.2.Surgically Implanted PNS stimulators: Obesity
6.14.3.Surgically Implanted PNS stimulators: Epilepsy
6.14.4.Surgically Implanted PNS stimulators: Incontinence
6.14.5.Surgically Implanted PNS stimulators: Tinnitus
6.14.6.VNS Therapy System: Depression & Epilepsy
6.15.vBloc® neurometabolic therapy : Weight loss
6.16.InterStim™ system: Bladder control & Fecal Incontinence
6.17.Paired Vagus Nerve Stimulation System : Chronic tinnitus
6.18.Invasive PNS stimulation: Summary
6.19.PNS: Non- Invasive
6.20.Non-Invasive PNS electro stimulators: Transcutaneous electrical nerve stimulation (TENS)
6.20.1.Non-Invasive PNS electro stimulators: ADHD
6.20.2.Non-Invasive PNS electro stimulators: Episodic chronic headache / migraine
6.21.Monarch external Trigeminal Nerve Stimulation : ADHD , Depression and Epilepsy non-invasively
6.22.GammaCore : Episodic cluster headache
6.23.Actipatch: Chronic pain relief
6.24.Quell : Chronic pain
6.25.Summary: Non- Invasive/ minimally invasive electro stimulators
6.26.CNS: Spinal Cord Stimulators & Deep Brain Stimulators
6.27.SCS: Overview
6.27.1.SCS: Components
6.28.NeuroBlock (NeuroStimulation):chronic low back pain
6.29.Axium™ Neurostimulator System : isolated chronic pain of the lower limbs, including the foot, knee, hip or groin
6.30.Reactiv-8 : Disabling chronic back pain
6.31.The Senza® system: Back and leg pain
6.32.SCS: Summary
6.33.DBS :Overview
6.33.1.DBS: Components
6.33.2.DBS: Parkinson Disease
6.34.Activa PC Neurostimulator: Neurological diseases/conditions
6.35.Picostim: Parkinson's disease
6.36.DBS: Summary
6.37.Electrical Neuromodulation technologies: The players
6.38.Electrical Neuromodulation technologies :All neuromodulation devices
6.38.1.Electrical Neuromodulation technologies: By type
6.38.2.Electrical Neuromodulation technologies : SCS
6.38.3.Electrical Neuromodulation technologies : DBS
6.38.4.Electrical Neuromodulation technologies : PNS
6.38.5.Electrical Neuromodulation technologies: Key competitors
6.39.Case study: TENS ( traditional + Advanced)
6.40.Electrical Neuromodulation technologies: The players
6.40.1.Electrical neuromodulation technologies: Patent evolution
6.40.2.Electrical neuromodulation technologies: Trends
6.40.3.Electrical Neuromodulation technologies trends(2) : GiMer Medical
6.40.4.Electrical Neuromodulation technologies trends(3): Nevro
6.41.Key Market players: The big three
6.42.Electrical Neuromodulation technologies: Take home messages
7.OTHER
7.1.Electrical stimulation devices: Other
7.2.Other Electrical stimulation devices: Diabetic foot ulcers
7.3.Other Electrical stimulation devices: Central Sleep Apnea
7.4.DIAPHRAGM PACING SYSTEM: Breathing Disorders (sleep apnea)
7.5.Advanced Microcurrent Technology: Wound Care (diabetic foot ulcers)
8.NEXT GENERATION
8.1.Next Generation bioelectronic medicine
8.2.Interdisciplinary approach
8.3.Next Generation bioelectronic medicines: Creation of a visceral nerve atlas
8.4.Next generation bioelectronic medicines: Neural interfacing technology
8.5.Next generation bioelectronic medicines: Ongoing research for the development of next generation bioelectronic medicines
8.6."Comprehensive structural and functional mapping of the mammalian cardiac nervous system"
8.7."Mapping the linkage between auricular vagus nerve receptors and cardiovagal modulation"
8.8."Soft, conformal wireless optoelectronic systems for the long-term neuromodulation of bladder function"
8.9."Neuromodulation for asthma"
8.10.Next generation bioelectronic medicines: Summary
9.FULL MARKET FORECAST
9.1.Forecast assumptions: Conclusions
9.2.Market Forecast: Pacemaker units by sales volume
9.2.1.Market Forecast: Pacemaker market value
9.3.Market forecast: ICD units by sales volume
9.3.1.Market forecast: ICD units by market value
9.4.Market forecast: Comparison of pacemaker and ICD unit sales
9.4.1.Market forecast: Comparison of pacemaker and ICD market value
9.5.Market forecast: SCS by unit sales
9.5.1.Market forecast: SCS market value
9.6.Market forecast: DBS by unit sales
9.6.1.Market forecast: DBS market value
9.7.Market forecast: PNS by unit sales
9.7.1.Market forecast: PNS by market value
9.8.Market forecast: SCS ,DBS, PNS unit sales
9.8.1.Market forecast: SCS, DBS ,PNS market value
9.9.Market value traditional TENS by units
9.9.1.Market value Traditional TENS units
9.10.Sales units advanced TENS devices
9.10.1.Market value advanced TENS devices
9.11.Comparison of sales units of Traditional TENS and Advanced TENS
9.11.1.Comparison of market value of Traditonal TENS and Advanced TENS
9.12.Sales units of all termed Bioelectronic Medicines
9.12.1.Market value of all termed bioelectronic medicine
10.FINAL THOUGHTS: TERMED BIOELECTRONIC MEDICINES
10.1.Bioelectronic Medicines: Conclusions
11.COMPANY PROFILES
 

About IDTechEx reports

What are the qualifications of the people conducting IDTechEx research?

Content produced by IDTechEx is researched and written by our technical analysts, each with a PhD or master's degree in their specialist field, and all of whom are employees. All our analysts are well-connected in their fields, intensively covering their sectors, revealing hard-to-find information you can trust.

How does IDTechEx gather data for its reports?

By directly interviewing and profiling companies across the supply chain. IDTechEx analysts interview companies by engaging directly with senior management and technology development executives across the supply chain, leading to revealing insights that may otherwise be inaccessible.
 
Further, as a global team, we travel extensively to industry events and companies to conduct in-depth, face-to-face interviews. We also engage with industry associations and follow public company filings as secondary sources. We conduct patent analysis and track regulatory changes and incentives. We consistently build on our decades-long research of emerging technologies.
 
We assess emerging technologies against existing solutions, evaluate market demand and provide data-driven forecasts based on our models. This provides a clear, unbiased outlook on the future of each technology or industry that we cover.

What is your forecast methodology?

We take into account the following information and data points where relevant to create our forecasts:
  • Historic data, based on our own databases of products, companies' sales data, information from associations, company reports and validation of our prior market figures with companies in the industry.
  • Current and announced manufacturing capacities
  • Company production targets
  • Direct input from companies as we interview them as to their growth expectations, moderated by our analysts
  • Planned or active government incentives and regulations
  • Assessment of the capabilities and price of the technology based on our benchmarking over the forecast period, versus that of competitive solutions
  • Teardown data (e.g. to assess volume of materials used)
  • From a top-down view: the total addressable market
  • Forecasts can be based on an s-curve methodology where appropriate, taking into account the above factors
  • Key assumptions and discussion of what can impact the forecast are covered in the report.

How can I be confident about the quality of work in IDTechEx reports?

Based on our technical analysts and their research methodology, for over 25 years our work has regularly received superb feedback from our global clients. Our research business has grown year-on-year.
 
Recent customer feedback includes:
"It's my first go-to platform"
- Dr. Didi Xu, Head of Foresight - Future Technologies, Freudenberg Technology Innovation
 
"Their expertise allows us to make data-driven, strategic decisions and ensures we remain aligned with the latest trends and opportunities in the market."
- Ralf Hug, Global Head of Product Management & Marketing, Marquardt

What differentiates IDTechEx reports?

Our team of in-house technical analysts immerse themselves in industries over many years, building deep expertise and engaging directly with key industry players to uncover hard-to-find insights. We appraise technologies in the landscape of competitive solutions and then assess their market demand based on voice-of-the-customer feedback, all from an impartial point of view. This approach delivers exceptional value to our customers—providing high-quality independent content while saving customers time, resources, and money.

Why should we pick IDTechEx research over AI research?

A crucial value of IDTechEx research is that it provides information, assessments and forecasts based on interviews with key people in the industry, assessed by technical experts. AI is trained only on content publicly available on the web, which may not be reliable, in depth, nor contain the latest insights based on the experience of those actively involved in a technology or industry, despite the confident prose.

How can I justify the ROI of this report?

Consider the cost of the IDTechEx report versus the time and resources required to gather the same quality of insights yourself. IDTechEx analysts have built up an extensive contact network over many years; we invest in attending key events and interviewing companies around the world; and our analysts are trained in appraising technologies and markets.
 
Each report provides an independent, expert-led technical and market appraisal, giving you access to actionable information immediately, rather than you having to spend months or years on your own market research.

Can I speak to analysts about the report content?

All report purchases include up to 30 minutes of telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.

What is the difference between a report and subscription?

A subscription from IDTechEx can include more reports, access to an online information platform with continuously updated information from our analysts, and access to analysts directly.

Before purchasing, I have some questions about the report, can I speak to someone?

Please email research@idtechex.com stating your location and we will quickly respond.

About IDTechEx

Who are IDTechEx's customers?

IDTechEx has served over 35,000 customers globally. These range from large corporations to ambitious start-ups, and from Governments to research centers. Our customers use our work to make informed decisions and save time and resources.

Where is IDTechEx established?

IDTechEx was established in 1999, and is headquartered in Cambridge, UK. Since then, the company has significantly expanded and operates globally, having served customers in over 80 countries. Subsidiary companies are based in the USA, Germany and Japan.

Questions about purchasing a report

How do I pay?

In most locations reports can be purchased by credit card, or else by direct bank payment.

How and when do I receive access to IDTechEx reports?

When paying successfully by credit card, reports can be accessed immediately. For new customers, when paying by bank transfer, reports will usually be released when the payment is received. Report access will be notified by email.

How do I assign additional users to the report?

Users can be assigned in the report ordering process, or at a later time by email.

Can I speak to someone about purchasing a report?

Please email research@idtechex.com stating your location and we will quickly respond.
 
The market value for Bioelectronic medicines may reach $21 billion by 2027

报告统计信息

幻灯片 224
预测 2027
 

Customer Testimonial

quote graphic
"The resources provided by IDTechEx, such as their insightful reports and analysis, engaging webinars, and knowledgeable analysts, serve as valuable tools and information sources... Their expertise allows us to make data-driven, strategic decisions and ensures we remain aligned with the latest trends and opportunities in the market."
Global Head of Product Management and Marketing
Marquardt GmbH
 
 
 

Subscription Enquiry